Specifically, decreased expression has been shown to improve the prognosis of breast cancer and HCC patients [76, 82], Alternatively, the presence of PRMT2 has been shown to inhibit NF-κB response and induce apoptosis by blocking the export of IκBα [83]. Here, PRMT2 is linked to breast carcinoma.